Document Detail


Effects of the diazafluoranthen derivative AC-3579 (NSC-170561), a new experimental antitumour drug, on rat hepatoma.
MedLine Citation:
PMID:  174050     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of AC-3579 (NSC-170561), a new experimental antitumour drug which depresses phospholipid catabolism in liver, were compared in rat aflatoxin-induced hepatoma and in non-neoplastic hepatocytes surrounding the tumour. Ultrastructural lesions, characterized by the hypertrophy of the smooth endoplasmic reticulum and the presence of lamellate cytosomes appeared in both tissues. They were less marked in hepatoma than in non-neoplastic cells. As in control livers, they were related to an invrease in pohspholipid concentration due to the decrease of phospholipid breakdown. In addition, chemical analysis demonstrated differences between hepatoma, non-neoplastic aflatoxin-treated liver and control liver: total and free cholesterol were decreased, relative concentration of sphingomyelin increased and that of phosphatidylethanolamine decreased by about 50%, in both hepatoma and non-neoplastic liver. Phospholipid concentration was decreased by 50% in tumour cells. After AC-3579 treatment total cholesterol was increased 3.2 fold in non-neoplastic liver and 2.5 fold in hepatoma but not in control liver.
Authors:
O Thys; J Hildebrand; Y Gerin
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Pathologia Europaea     Volume:  10     ISSN:  0031-2967     ISO Abbreviation:  Pathol Eur     Publication Date:  1975  
Date Detail:
Created Date:  1976-04-01     Completed Date:  1976-04-01     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0062702     Medline TA:  Pathol Eur     Country:  BELGIUM    
Other Details:
Languages:  eng     Pagination:  251-62     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aflatoxins
Animals
Antineoplastic Agents / pharmacology,  therapeutic use*
Aza Compounds / pharmacology,  therapeutic use*
Carcinoma, Hepatocellular / chemically induced,  drug therapy*,  metabolism,  pathology
Endoplasmic Reticulum / drug effects
Fluorenes / pharmacology,  therapeutic use*
Liver / drug effects,  metabolism,  ultrastructure
Liver Neoplasms / chemically induced,  drug therapy*,  metabolism,  pathology
Male
Neoplasms, Experimental / chemically induced,  drug therapy,  metabolism,  pathology
Phosphates / metabolism
Rats
Chemical
Reg. No./Substance:
0/Aflatoxins; 0/Antineoplastic Agents; 0/Aza Compounds; 0/Fluorenes; 0/Phosphates

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A study of the immuno-suppressive activity of Herpes simplex virus type 2 and the tumor enhancing po...
Next Document:  Fat accumulation in tha adrenal gland: effect of oestradiol benzoate on the zona reticularis of the ...